Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
暂无分享,去创建一个
S. Wilhelm | J. Gollob | C. Carter | S. Kelley | Jared A Gollob | Scott Wilhelm | Chris Carter | Susan L Kelley
[1] K. Flaherty,et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Bartlett,et al. Raf‐1 expression may influence progression to androgen insensitive prostate cancer , 2005, The Prostate.
[3] K. Peggs. Imatinib mesylate—gold standards and silver linings , 2004, Clinical and Experimental Medicine.
[4] A. Norman,et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.
[5] A. El‐Naggar,et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. , 2001, The American journal of pathology.
[6] Z. Hao,et al. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. , 1997, Biochemical and biophysical research communications.
[7] T. Habuchi,et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. , 2001, The Tohoku journal of experimental medicine.
[8] J. Minna,et al. Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[9] Sridhar Ramaswamy,et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.
[10] Lisa M. Schwartz,et al. Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.
[11] E. Sausville,et al. Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.
[12] I. Herman,et al. Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.
[13] K. Fang,et al. Transfection of anti‐sense complementary DNA of human epidermal‐growth‐factor receptor attenuates the proliferation of human non‐small‐cell‐lung‐cancer cells , 1999, International journal of cancer.
[14] J. Melo,et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. , 2005, Cancer research.
[15] S. Barni,et al. Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients , 2000, Urologia Internationalis.
[16] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[17] B. Monia,et al. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. , 2002, Cancer research.
[18] M. Schwab,et al. Amplification of oncogenes revisited: from expression profiling to clinical application. , 2001, Cancer letters.
[19] D. Lowy,et al. Function and regulation of ras. , 1993, Annual review of biochemistry.
[20] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[21] W. Kolch. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.
[22] R. Bukowski,et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Wagner,et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene , 2001, The EMBO journal.
[24] M. Kruhøffer,et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. , 2005, The Journal of clinical investigation.
[25] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[27] S. Korsmeyer,et al. VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis , 2003, Science.
[28] J. Deddens,et al. Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis , 2004, Clinical Cancer Research.
[29] L. Goodglick,et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. , 2004, Advances in cancer research.
[30] S. S. Koh,et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[31] Y. Nikiforov,et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.
[32] W. Kolch,et al. Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.
[33] J. Martinou,et al. The Bcl-2 protein family. , 2000, Experimental cell research.
[34] A. Teramoto,et al. Hypoxia Inducible Factor 1-α Regulates of Platelet Derived Growth Factor-B in Human Glioblastoma Cells , 2005, Journal of Neuro-Oncology.
[35] E. Small,et al. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Amadori,et al. 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) , 2004 .
[37] Walter Kolch,et al. Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.
[38] E. Keller,et al. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein , 2005, Journal of cellular biochemistry.
[39] M. Edin,et al. Raf-1 Serine 338 Phosphorylation Plays a Key Role in Adhesion-Dependent Activation of Extracellular Signal-Regulated Kinase by Epidermal Growth Factor , 2005, Molecular and Cellular Biology.
[40] P. Bunn,et al. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. , 2004, International journal of radiation oncology, biology, physics.
[41] P. V. van Diest,et al. Hypoxia‐inducible factor‐1α is associated with angiogenesis, and expression of bFGF, PDGF‐BB, and EGFR in invasive breast cancer , 2005 .
[42] C. Moroni,et al. Reversible abrogation of IL‐3 dependence by an inducible H‐ras oncogene. , 1989, The EMBO journal.
[43] M. Shibuya,et al. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. , 2005, Clinical science.
[44] D. Stupack,et al. Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.
[45] O. Scharovsky,et al. Inhibition of ras oncogene: a novel approach to antineoplastic therapy. , 2000, Journal of biomedical science.
[46] C. Rudin,et al. Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors , 2004, Clinical Cancer Research.
[47] Audy G. Whitman,et al. Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors , 2005, Leukemia.
[48] A. Dritschilo,et al. RAF antisense oligonucleotide as a tumor radiosensitizer , 2003, Oncogene.
[49] L. Neckers,et al. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents , 2002, Expert opinion on emerging drugs.
[50] Napoleone Ferrara,et al. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.
[51] M. Wigler,et al. Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[52] D. Fraker,et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. , 2005, Cancer research.
[53] M. Meyer,et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients , 2005 .
[54] Guojun Wu,et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. , 2005, The Journal of clinical endocrinology and metabolism.
[55] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[56] G. Schweizer-Groyer,et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. , 2004, Biochemical pharmacology.
[57] M. Comalada,et al. Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis. , 2001, Immunobiology.
[58] T. Golub,et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.
[59] T. Wirth,et al. Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[60] Y. Kloog,et al. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. , 2004, Cellular signalling.
[61] B. Escudier,et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. , 2000, The cancer journal from Scientific American.
[62] T. Kuriyama,et al. NIH3T3 transfectant containing human K-ras oncogene shows enhanced metastatic activity after in vivo tumor growth or co-culture with fibroblasts , 1992, Clinical & Experimental Metastasis.
[63] D. Tuveson,et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.
[64] D. Polsky,et al. Clinical significance of BRAF mutations in metastatic melanoma , 2004, Journal of Translational Medicine.
[65] T. Whiteside,et al. Activation of Raf by ionizing radiation , 1996, Nature.
[66] G. Thakker,et al. Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells , 2003, Molecular Cancer.
[67] C. Marshall,et al. Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.
[68] J. Inazawa,et al. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines , 2004, Oncogene.
[69] M. Nikiforova,et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.
[70] J. Field,et al. p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association* , 2005, Journal of Biological Chemistry.
[71] M. Ratain,et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[72] Alexander Levitzki,et al. Activation of the Ras/Mitogen-Activated Protein Kinase Pathway by Kinase-Defective Epidermal Growth Factor Receptors Results in Cell Survival but Not Proliferation , 1998, Molecular and Cellular Biology.
[73] Jing Chen,et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] D. McDonald,et al. Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.
[76] J. Fleming,et al. Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy , 2005, Molecular Cancer Research.
[77] Huber Be,et al. Expression and phenotypic alterations caused by an inducible transforming ras oncogene introduced into rat liver epithelial cells. , 1988 .
[78] B. Calabretta,et al. Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant , 1998, The Journal of experimental medicine.
[79] M. Gore,et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Hong Wk,et al. Prevention of lung cancer. The new millennium. , 2000 .
[81] Giulio Superti‐Furga,et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.
[82] E. Eisenhauer,et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[83] Peter J. Keller,et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer , 2006, The Prostate.
[84] R. Bukowski,et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[85] E. Dmitrovsky,et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[86] M Paesmans,et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.
[87] P. Khavari,et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations , 2005, Nature Genetics.
[88] J. Troppmair,et al. The ins and outs of Raf kinases. , 1994, Trends in biochemical sciences.
[89] R. Benz,et al. Negative regulation of mitochondrial VDAC channels by C-Raf kinase , 2002, BMC Cell Biology.
[90] Rui Qiao,et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. , 2003, Cancer research.
[91] Analysis of the transcriptional program induced by Raf in epithelial cells , 2001 .
[92] P. LoRusso,et al. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer , 2005 .
[93] L. Gunaratnam,et al. Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.
[94] B. Monia,et al. Antisense Oligonucleotide Targeting of Raf-1 , 2004, Clinical Cancer Research.
[95] A. Harris,et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. , 2002, Cancer research.
[96] B. Monia,et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer , 2001 .
[97] T. Sugimura,et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. , 1994, Cancer research.
[98] W. Kaelin,et al. Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.
[99] G. Goodman,et al. Prevention of lung cancer. , 2000, Critical reviews in oncology/hematology.
[100] D. Elder,et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.
[101] A. Strasser,et al. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. , 2002, Journal of cell science.
[102] Larsson Li. Novel actions of tyrphostin AG 879: inhibition of RAF-1 and HER-2 expression combined with strong antitumoral effects on breast cancer cells. , 2004 .
[103] G. Evan,et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.
[104] P. Dent,et al. Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.
[105] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[106] S. Cartlidge,et al. 368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor , 2004 .
[107] E. Kohn,et al. The new millennium , 2000, Cancer.
[108] C. Borner. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. , 2003, Molecular immunology.
[109] K. Guan,et al. Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.
[110] E. Eisenhauer,et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[111] K. Hemminki,et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. , 2005, The Journal of investigative dermatology.
[112] M. Sporn. The war on cancer , 1996, The Lancet.
[113] S. Horvath,et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.
[114] G. Gores,et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. , 2002, Cancer research.
[115] J. Lee,et al. Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression , 2001, Journal of surgical oncology.
[116] L. Aaltonen,et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.
[117] U. Naumann,et al. The role of Raf kinases in development and growth of tumors. , 1997, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[118] H. Ishida,et al. Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma , 2002, Cancer.
[119] W. Kolch,et al. The Role of Raf Kinases in Malignant Transformation , 2022 .
[120] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[121] P. Bertics,et al. Inhibition of epidermal growth factor/transforming growth factor‐α–stimulated cell growth by a synthetic peptide , 1989, Journal of cellular physiology.
[122] O Yoshida,et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.
[123] C. Ryan,et al. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. , 2001, Clinical colorectal cancer.
[124] S. Chan,et al. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer , 2004, British Journal of Cancer.
[125] G. Vlastos,et al. Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries , 2004, BMC Cancer.
[126] M. Sabripour,et al. Imatinib resistance in gastrointestinal stromal tumors , 2005, Current oncology reports.
[127] G. Gores,et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.
[128] J. Radulovic,et al. Phosphorylation of Hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during Contextual Fear Conditioning: Interactions between Erk-1/2 and Elk-1 , 2002, Molecular and Cellular Neuroscience.
[129] G. Niehans,et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[130] T. Golub,et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.
[131] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[132] Walter Kolch,et al. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. , 2005, Cancer research.
[133] J. Small,et al. Raf-1 regulates Rho signaling and cell migration , 2005, The Journal of cell biology.
[134] F. Koga,et al. Higher expression of K‐ras is associated with parathyroid hormone‐related protein‐induced hypercalcaemia in renal cell carcinoma , 2001, BJU international.
[135] E. Eisenhauer,et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). , 2003, Gynecologic oncology.
[136] R. Marais,et al. The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.
[137] L. Gunaratnam,et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.
[138] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] S. Kong,et al. The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells. , 2004, Oncology reports.
[140] W. Kolch,et al. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. , 2005, Cancer research.
[141] J. Folkman,et al. The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.
[142] Y. Fukushima,et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. , 1999, European journal of cancer.
[143] Theresa M. Grana,et al. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. , 2002, Cancer research.
[144] P. Jänne,et al. Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474 , 2005 .
[145] M. Konopleva,et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[146] S. Yuspa,et al. Keratinocytes blocked in phorbol ester-responsive early stage of terminal differentiation by sarcoma viruses , 1985, Nature.
[147] S. H. Lee,et al. Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. , 1996, Cancer letters.
[148] C. Pritchard,et al. MEK kinase activity is not necessary for Raf‐1 function , 2001, The EMBO journal.
[149] H. Radzun,et al. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas , 2001, Virchows Archiv.
[150] H. Cortés-Funes. New treatment approaches for lung cancer and impact on survival. , 2002, Seminars in oncology.